A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses

Journal of Immunology

Volumn 170, Issue 8, 2003, Pages 4242-4253

  Dakappagari, Naveen K ^a   Pyles, John ^a   Parihar, Robin ^a   Carson, William E ^a,b   Young, Donn C ^a,b   Kaumaya, Pravin T P ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Tzagournis Medical Research Facility   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; HYBRID PROTEIN; MEASLES VIRUS FUSION PROTEIN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2[316-339]; MEASLES VIRUS FUSION PROTEIN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2[485-503]; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; COMPUTER ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; EXTRACELLULAR SPACE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; ISOGRAFT; LUNG METASTASIS; MEASLES VIRUS; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RABBIT; TUMOR CELL; VACCINATION;

EID: 0037446525     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.8.4242     Document Type: Article

References (90)

1. Hynes, N. E., and D. F. Stern. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198:165.
2. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177.
3. Slamon, D. J., and G. M. Clark. 1988. Amplification of c-erbB-2 and aggressive human breast tumors? Science 240:1795.
4. Allred, D. C., G. M. Clark, A. K. Tandon, R. Molina, D. C. Tormey, C. K. Osborne, K. W. Gilchrist, E. G. Mansour, M. Abeloff, L. Eudey, et al. 1992. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 10:599.
5. Burke, H. B., A. Hoang, J. D. Iglehart, and J. R. Marks. 1998. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 82:874.
6. Pegram, M. D., G. Pauletti, and D. J. Slamon. 1998. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52:65.
7. Disis, M. L., and M. A. Cheever. 1997. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. 71:343.
8. Drebin, J. A., V. C. Link, D. F. Stern, R. A. Weinberg, and M. I. Greene. 1985. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:697.
9. Klapper, L. N., H. Waterman, M. Sela, and Y. Yarden. 2000. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60:3384.
10. Katsumata, M., T. Okudaira, A. Samanta, D. P. Clark, J. A. Drebin, P. Jolicoeur, and M. I. Greene. 1995. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat. Med. 1:644.
11. Cobleigh, M. A., C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, et al. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639.
12. Disis, M. L., E. Calenoff, G. McLaughlin, A. E. Murphy, W. Chen, B. Groner, M. Jeschke, N. Lydon, E. McGlynn, R. B. Livingston, et al. 1994. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:16.
13. Disis, M. L., S. M. Pupa, J. R. Gralow, R. Dittadi, S. Menard, and M. A. Cheever. 1997. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 15:3363.
14. Esserman, L. J., T. Lopez, R. Montes, L. N. Bald, B. M. Fendly, and M. J. Campbell. 1999. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol. Immunother. 47:337.
15. Amici, A., A. Smorlesi, G. Noce, G. Santoni, P. Cappelletti, L. Capparuccia, R. Coppari, R. Lucciarini, C. Petrelli, and M. Provinciali. 2000. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/nue transgenic mice. Gelle Ther. 7:703.
16. Reilly, R. T., M. B. Gottlieb, A. M. Ercolini, J. P. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60:3569.
17. Sfondrini, L., M. Rodolfo, M. Singh, M. P. Colombo, M. I. Colnaghi, S. Menard, and A. Balsari. 2000. Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice. Cancer Res. 60:3777.
18. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455.
19. Bernards, R., A. Destree, S. McKenzie, E. Gordon, R. A. Weinberg, and D. Panicali. 1987. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc. Natl. Acad. Sci. USA 84:6854.
20. Disis, M. L., J. R. Gralow, H. Bernhard, S. L. Hand, W. D. Rubin, and M. A. Cheever. 1996. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu. oncogenic self-protein. J. Immunol. 156:3151.
21. Stancovski, I., E. Hurwitz, O. Leitner, A. Ullrich, Y. Yarden, and M. Sela. 1991. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA 88:8691.
22. Hurwitz, E., I. Stancovski, M. Sela, and Y. Yarden. 1995. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. USA 92:3353.
23. Nagata, Y., R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, K. Furukawa, H. Nakamura, T. Kanematsu, and H. Shiku. 1997. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159:1336.
24. Dakappagari, N. K., D. B. Douglas, P. L. Triozzi, V. C. Stevens, and P. T. Kaumaya. 2000. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 60:3782.
25. Serody, J. S., E. J. Collins, R. M. Tisch, J. J. Kuhns, and J. A. Frelinger. 2000. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J. Immunol. 164:4961.
26. Disis, M. L., K. H. Grabstein, P. R. Sleath, and M. A. Cheever. 1999. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5:1289.
27. Brossart, P., S. Wirths, G. Stuhler, V. L. Reichardt, L. Kanz, and W. Brugger. 2000. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102.
28. Knutson, K. L., K. Schiffman, and M. L. Disis. 2001. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107:477.
29. Kaumaya, P. T. P., S. Kobs-Conrad, A. M. DiGeorge, and V. Stevens. 1994. Denovo engineering of protein immunogenic and antigenic determinants. In Peptides, Vol. 9. G. M. B. Anantharamaiah, ed. Springer-Verlag, New York, p. 133.
30. Hopp, T. P., and K. R. Woods. 1981. Prediction of protein antigenic determinants from amino acid sequences. Proc. Natl. Acad. Sci. USA 78:3824.
31. Parker, J. M., D. Guo, and R. S. Hodges, 1986. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 25:5425.
32. Janin, J. 1979. Surface and inside volumes in globular proteins. Nature 277:491.
33. Novotń J., M. Handschumacher, E. Haber, R. E. Bruccoleri, W. B. Carlson, D. W. Fanning, J. A. Smith, and G. D. Rose. 1986:Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). Proc. Natl. Acad. Sci. USA 83:226.
34. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein, J. Mol. Biol, 157:105,
35. Welling, G. W., W. J. Weijer, R. van der Zee, and S. Welling-Wester. 1985. Prediction of sequential antigenic regions in proteins. FEBS Lett. 188:215.
36. Manavalan, P., and P. K. Ponnuswamy. 1978. Hydrophobic character of amino acid residues in globular proteins. Nature 275:673.
37. Chou, P. Y., and G. D. Fasman. 1978. Prediction of the secondary structure of proteins from their amino acid sequence. Adv. Enzymol. Relat. Areas Mol. Biol. 47:45.
38. Kobs-Conrad. S., H. Lee, A. M. DiGeorge, and P. T. Kaumaya. 1993. Engineered topographic determinants with αβ, βαβ, and βαβα topologies show high affinity binding to native protein antigen (lactate dehydrogenase-C4). J. Biol. Chem. 268:25285.
39. Houghten, R. A., and C. H. Li. 1976. Studies on pituitary prolactin. 39. Reaction of the ovine hormone with hydrogen peroxide. Biochim. Biophys. Acta 439:240.
40. Houghten, R. A., and C. H. Li, 1979. Reduction of sulfoxides in peptides and proteins. Anal. Biochem. 98:36.
41. Chen, Y. H., J. T. Yang, and K. H. Chau. 1974. Determination of the helix and β form of proteins in aqueous solution by circular dichroism. Biochemistry 13:3350.
42. Greenfield, N., and G. D. Fasman. 1969. Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry 8:4108.
43. Hansen, M. B., S. E. Nielsen, and K. Berg. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119:203.
44. Maurer-Gebhard, M., M. Schmidt, M. Azemar, U. Altenschmidt, E. Stocklin, W. Wels, and B. Groner. 1998. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res. 58:2661.
45. Dunnett, C. 1955. A multiple comparison procedure for comparing treatments with a control. J. Am. Stat. Assoc. 50:1096.
46. Hopp, T. P. 1986. Protein surface analysis: methods for identifying antigenic determinants and other interaction sites. J. Immunol. Methods 88:1.
47. Thornton, J. M., M. S. Edwards, W. R. Taylor, and D. J. Barlow. 1986. Location of 'continuous' antigenic determinants in the protruding regions of proteins. EMBO J. 5:409.
48. Jameson, B. A., and H. Wolf. 1988. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput. Appl. Biosci. 4:181.
49. Klapper, L. N., N. Vaisman, E. Hurwitz, R. Pinkas Kramarski, Y. Yarden, and M. Sela. 1997. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14:2099.
50. Abe, Y., M. Odaka, F. Inagaki, I. Lax, J. Schlessinger, and D. Kohda. 1998. Disulfide bond structure of human epidermal growth factor receptor. J. Biol. Chem. 273:11150.
51. Yamamoto, T., S. Ikawa, T. Akiyama, K. Semba, N. Nomura, N. Miyajima, T. Saito, and K. Toyoshima. 1986. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230.
52. Partidos, C. D., and M. W. Steward. 1990. Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. J. Gen. Virol. 71:2099.
53. Kaumaya, P. T. P. 1996. Synthetic peptide vaccines: dream of reality. In Peptides in Immunology, C. H. Schneider, ed. Wiley & Sons, London, p. 117.
54. Schwartz, R. H., B. S. Fox, E. Fraga, C. Chen, and B. Singh. 1985. The T lymphocyte response to cytochrome c. V. Determination of the minimal peptide size required for stimulation of T cell clones and assessment of the contribution of each residue beyond this size to antigenic potency. J. Immunol. 135:2598.
55. Carbone, F. R., B. S. Fox. R. H. Schwartz, and Y. Paterson. 1987. The use of hydrophobic. α-helix-defined peptides in delineating the T cell determinant for pigeon cytochrome c. J. Immunol. 138:1838.
56. Naquet, P., J. Ellis, B. Singh, R. S. Hodges, and T. L. Delovitch. 1987. Processing and presentation of insulin. I. Analysis of immunogenic peptides and processing requirements for insulin A loop-specific T cells. J. Immunol. 139:3955.
57. Kaumaya, P. T., S. Kobs-Conrad, Y. H. Seo, H. Lee, A. M. VanBuskirk, N. Feng, J. F. Sheridan, and V. Stevens. 1993. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. J. Mol. Recognit. 6:81.
58. Hudziak, R. M., G. D. Lewis, M. Winget, B. M. Fendly, H. M. Shepard, and A. Ullrich. 1989. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9:1165.
59. van Leeuwen, F., M. J. van de Vijver, J. Lomans, L. van Deemter, G. Jenster, T. Akiyama, T. Yamamoto, and R. Nusse. 1990. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies. Oncogene 5:497.
60. Drebin, J. A., V. C. Link, and M. I. Greene. 1988. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2:273.
61. Kasprzyk, P. G., S. U. Song, P. P. Di Fiore, and C. R. King. 1992. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. 52:2771.
62. Harwerth, I. M., W. Wels, J. Schlegel, M. Muller, and N. E. Hynes. 1993. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 68:1140.
63. Xu, F., R. Lupu, G. C. Rodriguez, R. S. Whitaker, M. P. Boente, A. Berchuck, Y. Yu, K. A. DeSombre. C. M. Boyer, and R. C. Bast. 1993. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int. J. Cancer 53:401.
64. Sliwkowski, M. X., J. A. Lofgren, G. D. Lewis, T. E. Hotaling, B. M. Fendly, and J. A. Fox. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin). Semin. Oncol. 26:60.
65. Lewis, G. D., I. Figari, B. Fendly, W. L. Wong, P. Carter, C. Gorman, and H. M. Shepard. 1993. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37:255.
66. Clynes, R. A., T. L. Towers. L. G. Presta. and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443.
67. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95:7556.
68. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
69. Dighe, A. S., E. Richards, L. J. Old, and R. D. Schreiber. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity 1:447.
70. Klouche, M., H. Kirchner, and F. Holzel. 1995. Antiproliferative and recovery effects during treatment of breast and ovarian carcinoma cell cultures with interferon-γ J. Interferon Cytokine Res. 15:285.
71. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25.
72. Noguchi, Y., E. C. Richards, Y. T. Chen, and L. J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
73. Gan, Y. H., Y. Zhang, H. E. Khoo, and K. Esuvaranathan. 1999. Antimmour immunity of bacillus Calmette-Gu[caute]erin and interferon α in murine bladder cancer. Eur. J. Cancer 35:1123.
74. Eisenthal, A., R. B. Cameron, and S. A. Rosenberg. 1990. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-α and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J. Immunol. 144:4463.
75. Rodolfo, M., C. Zilocchi, C. Melani, B. Cappetti, I. Arioli. G. Parmiani, and M. P. Colombo. 1996. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens: comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol. 157:5536.
76. Adris, S., E. Chuluyan, A. Bravo, M. Berenstein, S. Klein, M. Jasnis, C. Carbone. Y. Chernajovsky, and O. L. Podhajcer. 2000. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells. Cancer Res. 60:6696.
77. Grob, P. J., H. I. Joller-Jemelka, U. Binswanger, K. Zaruba, C. Descoeudres, and M. Fernex. 1984. Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations. Eur. J. Clin. Microbiol. 3:195.
78. Sturchler, D., R. Berger, H. Etlinger, M. Fernex, H. Matile, R. Pink, V. Schlumbom, and M. Just. 1989. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults. Vaccine 7:457.
79. Bliss, J., R. Maylor, K. Stokes, K. S. Murray, M. A. Ketchum, and S. F. Wolf. 1996. Interleukin-12 as vaccine adjuvant. Characteristics of primary, recall, and long-term responses. Ann. NY Acad. Sci. 795:26.
80. Bliss, J., V. Van Cleave, K. Murray, A. Wiencis, M. Ketchum, R. Maylor, T. Haire, C. Resmini, A. K. Abbas, and S. F. Wolf. 1996. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J. Immunol. 156:88Z
81. Metzger, D. W., J. M. Buchanan, J. T. Collins, T. L. Lester, K. S. Murray, V. H. Van Cleave, L. A. Vogel, and W. A. Dunnick. 1996. Enhancement of humoral immunity by interleukin-12. Ann. NY Acad. Sci. 795:100.
82. Schijns, V. E., K. C. Weining, P. Nuijten, E. O. Rijke, and P. Staeheli. 2000. Immunoadjuvant activities of E. coli- and plasmid-expressed recombinant chicken IFN-α/β, IFN-γ and IL-1β in 1-day and 3-week-old chickens. Vaccine 18:-2147.
83. + tumors. Cancer Res. 58:4902.
84. Lairmore, M. D., A. M. DiGeorge, S. F. Conrad, A. V. Trevino, R. B. LaI, and P. T. Kaumaya. 1995. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction. J. Virol. 69:6077.
85. Bakaletz, L. O., E. R. Leake, J. M. Billy, and P. T. Kaumaya. 1997. Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chinchilla. Vaccine 15:955.
86. Herlyn, D., and H. Koprowski. 1982. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA 79:4761.
87. Herlyn, D., M. Herlyn, Z. Steplewski, and H. Koprowski. 1985. Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells. Cell. Immunol. 92:105.
88. Drebin, J. A., V. C. Link, and M. I. Greene. 1988. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2:387.
89. Lane, H. A., I. Beuvink, A. B. Motoyama, J. M. Daly, R. M. Neve, and N. E. Hynes. 2000. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 20:3210.
90. Peng, L. S., M. L. Penichet, and S. L. Morrison. 1999. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163:250.